Ferring Pharmaceuticals agreed to buy fertility treatment startup Gameto in a deal potentially valued at up to $1.4 billion with payments tied to development, regulatory, and sales milestones. Gameto’s platform centers on “Fertilo,” using stem cell-derived ovarian support cells to grow eggs outside the body, aiming to reduce reliance on hormone injections and shorten IVF cycle timelines.